StreetInsider.com News Articles

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Nova Pneuma Inc. ("NPI"), the Delaware incorporated and wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisition from Alexza Pharmaceuticals, Inc. ("Alexza"). The transaction grants Lee's Pharm and NPI, the full ownership of

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB

Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights

Tue, 09 Dec 2025 08:00:00 -0400

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential
Synergistic and complementary to Lee's Pharm's existing products pipeline, and
Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB